1. AIMS & SCOPE — Epitheorese Klinikes Farmakologias kai Farmakokinetikes (ISSN-print: 1011-6575; ISSN-electronic: 2945-1914) is an open-access, peer-reviewed journal aiming to promote optimum drug therapy by publishing articles that address important aspects and challenges faced in the wider fields of Clinical and Applied Pharmacology, Medicine, and Therapeutics.
2. ARTICLE TYPES — Epitheorese Klinikes Farmakologias kai Farmakokinetikes considers and publishes manuscripts for the following 10 article types: case report, commentary, correspondence, editorial, evidence synthesis, guidelines, hypothesis, meeting report, notes, obituary, opinion, protocol, research report, review, and tutorial.
2.1. Case Report — The journal considers case reports that: (i) focus on previously unreported or unusual drug side effects, (ii) highlight adverse interactions involving medications, (iii) report unexpected or unusual presentations of a disease that could have an impact on its treatment strategy, (iv) contribute novel findings regarding the management of new and emerging diseases, (v) describe an unexpected event in the course of treating a patient, and/or (vi) shed light on the pathogenesis of an adverse effect. Case report manuscripts not meeting at least one of the aforementioned criteria will not be considered for publication in this journal.
2.2. Correspondence — Correspondence is limited to the communication of specific arguments, comments, and data relevant to articles already published in the journal. If the manuscript is deemed worthy of publication after peer-review, a response is commissioned by the editor-in-chief. The fees of any responses are waived.
2.3. Editorial — Editorials are authored exclusively by the journal’s editor-in-chief, consulting and proceedings editor, editorial board members, or guest editors. They reflect the journal’s position on timely developments and challenges faced by the pharmacological community, or introduce the content of supplementary issues. The fees of editorials are waived.
2.4. Evidence Synthesis — Systematic reviews and meta-analyses represent the two major forms of evidence synthesis that the journal publishes, where information is brought together from a range of sources in order to inform a debate or a decision on a specific issue. Manuscripts for this article type should identify gaps in knowledge, answer a specific research question, and establish an evidence-based suggestion for the improvement of current practice or policy related to optimum drug therapy.
2.5. Meeting Report — Meeting reports summarize the key developments presented and discussed at a meeting. The latter could be a workshop or a seminar, a panel or round table discussion, a symposium, or a satellite event within a conference. The editor-in-chief will consider the publication of meeting reports focusing on topics that align well with the journal’s scope.
2.6. Notes — Manuscripts presenting the findings of historical research or providing insight to the history of drugs or of therapeutic strategies for a specific clinical entity, are welcomed by the journal and, if accepted for publication, will be published as notes.
2.7. Obituary — Obituaries communicate the recent death and, at the same time, celebrate the life and achievements of an eminent expert in a field aligned with those served by the journal. Obituaries can be solicited or unsolicited, but are always written by a colleague of the deceased who knew him/her well. The fees of obituaries are waived.
2.8. Opinion — Opinion articles can be solicited or unsolicited, written by established researchers (who are not members of the journal’s editorial board), and reflect their views on timely developments and challenges faced by the pharmacological community. The fees of solicited opinion articles are waived.
2.9. Research Report — Research reports can convey the findings of clinical, computational, epidemiological, or experimental research, even if these present negative results. In all cases, emphasis is given on the clarity of the findings’ presentation, the accuracy and completeness of the presentation of the methodology followed as well as its appropriateness for the hypothesis made, the robustness of the statistical analysis employed, and the validity of the conclusions reached. Manuscripts presenting previously published or flawed data, failing to disclose details regarding the ethical approval of their experiments or the informed consent of their patients, or refusing to provide raw data to the editor-in-chief or the reviewers if / when reasonably requested to so, will be rejected.
2.10. Review — Reviews should present balanced, well-informed, and well-written accounts of recent developments and ongoing challenges in the wider fields of Clinical and Applied Pharmacology, Medicine, and Therapeutics. Ideally, more than half of the references they cite need to have been published within the last five years.
3. ERRATA AND RETRACTION NOTES — The journal retains the right to publish errata and retraction notes. An erratum is published in order to correct mistakes or omissions caused by the author(s) of an article, that do not alter the conclusion of the said article. A retraction note is published when the conclusions of the article concerned are deemed unreliable due to the existence of serious ethical concerns, misconduct, or honest errors.
4. MANUSCRIPT PREPARATION — Manuscripts should adhere to the guidelines of the journal upon submission. Manuscripts that fail to do so will be returned to the corresponding authors.Table 1 summarizes the manuscript specifications for all 10 article types published in the regular and special issues of Epitheorese Klinikes Farmakologias kai Farmakokinetikes. Please note that manuscripts considered for publication as conference proceedings papers follow different specifications (see section 8 below).
| TABLE 1. Manuscript specifications for all 10 article types published in the regular and special issues of the journal Epitheorese Klinikes Farmakologias kai Farmakokinetikes. |
|
Case Report Commentary Correspondence Editorial Evidence Synthesis Notes Obituary Opinion Research Report Review |
4.1. Language — The journal accepts manuscripts written in Greek and English. In particular manuscripts written in English, the spelling could be either American or British as long as it is consistent throughout the manuscript. We highly recommend the use of editing services (particularly by authors who are non-native speakers of English) prior to the submission of a manuscript to the journal, as this will increase the chances of the manuscript to convey its message with clarity and accuracy. If the reviewers believe that the manuscript’s language bears significant issues, the editor-in-chief retains the right to request proof of the undertaking of professional editing as part of the revision process. Manuscripts submitted in the Greek language must include the title, authors’ names, affiliations, corresponding author details, and keywords in English, along with an English abstract placed at the end of the manuscript and before the references.
4.2. Templates — All manuscripts should be prepared based on the specifications found in Table 1 (when manuscripts are intended for publication in regular or special issues) or based on the specifications and the templates found in the conference website (when manuscripts are intended for publication in conference proceedings; see section 8). Manuscripts that fail to do so will be returned to the corresponding authors. The font and formatting arrangements of the templates must be respected. Footnotes are not allowed, and the adherence to the word limits must be strict.
4.3. Reporting Guidance — Authors are advised to consult the reporting guidance described in Table 1 where applicable: (i) the 2013 CARE checklist (for case reports), (ii) the PRISMA 2020 Statement (for evidence synthesis in the form of a meta-analysis or a systematic review), (iii) the AGREE Reporting Checklist (for guidelines), (iv) the SPIRIT 2013 Statement (for protocols), (v) the ARRIVE Guidelines 2.0 (for research reports that describe animal pre-clinical studies), (vi) the CONSORT 2010 Statement (for research reports that describe parallel group randomised trials), and (vii) the STROBE Statement(for research reports that describe cohort, case-control, or cross-sectional studies).
4.4. Nomenclature, Units, and Abbreviations — When preparing a manuscript, emphasis must be given to employing the appropriate and up-to-date nomenclature (see section 4.4.1), using accurate units of measurement (see section 4.4.2), and ensuring all used abbreviations are standard, well-defined or included in the journal’s list of abbreviations that need not be defined (see section 4.4.3).
4.4.1. Nomenclature — The accuracy of the nomenclature used, its relevance to the topic of the manuscript, as well its use in its most recently updated form, are essential aspects of effective scientific communication. Latin binomials (identifying species) and genes should be written in italics, and the same applies for quoted text, titles of works and journals, as well as the following terms: a posteriori, a priori, ad hoc, ad libitum, alma mater, ante cibum, ante mortem, de facto, de novo, erga omnes, errata, erratum, et al., etc., ex vivo, in memoriam, in naturo, in ovo, in silico, in situ, in vitro, in vivo, magna cum laude, materia medica, modus operandi, nil per os, per annum, per capita, per diem, per os, per rectum, per se, pro parte, pro rata, sic, status quo, terra incognita, terra nova, versus, veto, via, vice versa, and viva voce.
4.4.2. Units — All numerical values in the manuscript should be presented in accordance with the International System of Units (SI) base and derived units, as well as prefixes. Moreover, a space should be inserted between the value (in Arabic numeral) and the measurement unit, with the exception of values referring to degrees (°).
4.4.3. Abbreviations — All abbreviations should be defined upon first mention in the abstract as well as in the main text of the manuscript, and should be consistently used thereafter throughout these manuscript sections. Moreover, all abbreviations used in tables and/or figures need to also be defined in the respective legends. Abbreviations that need not be defined include: 2D, 3D, ADP, AMP, ANOVA, ATP, ATPase, AUC, BMI, BPS, BSA, cAMP, cDNA, CI, CoA, CT, DAPI, df, DMEM, DMSO, DNA, DNase, EC50, ECX, ECG, ED50, EDX, EDTA, EEA, EEG, eGFP, EGTA, ELISA, EMG, EPHAR, EU, FACS, FBS, FDA, FRET, GAPDH, GC, GC-MS, GDP, GFP, GMP, GTP, GTPase, Hb, HBSS, HEPES, HPLC, IC50, Ig, IL, IQ, IQR, IR, IU, IUPAC, IUPHAR, KO, LC, LC-MS, LED, LD50, LPS, MRI, mRNA, MS, MS-MS, MW, n, NAD+, NADH, NADP+, NADPH, NATO, NMR, OD, P, PBS, PCR, PET, pH, r, Rh, RIA, RIPA, RNA, RPMI, rRNA, SD, SDS-PAGE, SE, SEM, siRNA, SPSS, t1/2, TLC, Tris, tRNA, TUNEL, UAE, UK, UN, US, USA, UV, WHO, and WT. The definitions of the abbreviations that need not be defined can be found here.
4.5. References — Particular emphasis must also be given to the citation and formatting of the manuscript references based on the templates’ examples. References should be cited in order of appearance in the main text by citing the corresponding Arabic numeral in brackets. In the “References” section, references that correspond to journal articles with up to six authors should include all authors (i.e., the surname of each one followed by the initial of the name or names and of the middle name or names), while those with more than six authors should include the first six authors followed by the designation “et al.“. Journal abbreviations should follow the ISO-4 rules. Citing journal articles that have been published in languages other than English, dissertations, theses, or online material that has not been peer-reviewed should be avoided wherever possible.
4.6. Figures — Manuscripts submitted to the journal should contain high-quality figures that have been introduced as .jpeg files in the manuscript’s template (.docx file). The editorial office might request from the corresponding author to provide the original figure files during the article’s proof production. Moreover, the font of any text appearing in the figures should be Arial, at a size that is expected to be clear and legible when the image is printed within half the width of an A4 page.
4.7. Copyright — The use of any material that is subject to copyright is forbidden without the author(s) accurately acknowledging the source and obtaining the necessary permission from the copyright holder(s). Such a permission should be communicated to the editorial office within the cover letter and upon the manuscript submission. Failure to do so can result in the rejection of the manuscript or the retraction of the article.
5. MANUSCRIPT SUBMISSION — Manuscripts should be submitted through peer-review@ekff-ge.com. When submitting a manuscript to the journal, the corresponding author must submit three files: (i) a single manuscript file (in .docx form), (ii) a filled manuscript submission form (in .docx form), and (iii) a cover letter (in .pdf or .docx form). The journal’s editorial office will acknowledge receipt of the manuscript and provide a manuscript number within 72 h. Manuscripts that do not fulfil the specifications described in section 4 or lack the aforementioned documents, will be returned to the authors.
Please send us an email containing the following:
To:
peer-review@ekff-ge.com
Subject:
New manuscript submission – EKFFGE
Body:
Dear Editor-in-Chief,
Please find attached the required files for the consideration of our manuscript for publication by your respectful journal.
Sincerely,
…
Attachments:
- manuscript (file type: .docx; size limit: 15 MB) in which all figures derive from .jpeg or .tiff files
- manuscript submission form (file type: .docx; size limit: 2 MB)
- cover letter (file type: .docx or .pdf; size limit: 2 MB)
6. EDITORIAL WORKFLOW — The corresponding author is required to submit three files (see section 5 above) in order for the editor-in-chief to allow for a manuscript number assignment and decide whether to outright reject the manuscript or allow it to undergo peer reviewing. The reviewers return their comments to the editor-in-chief who then decides whether the manuscript should be rejected, accepted as is, or undergo a revision, and communicates the decision to the corresponding author. If given the opportunity, the corresponding author will submit a revised manuscript along with a filled peer review response form (which is provided to him/her) and any other material requested to the editor-in-chief, who will judge whether the revisions undertaken can allow for the revised manuscript to be accepted for publication or whether the revised manuscript needs to be forwarded to the reviewers for their input.
Once the reviewers have returned their comments regarding the revised manuscript, the editor-in-chief decides on whether the revised manuscript should be rejected, accepted, or undergo another (final) round of revision, and communicates the decision to the corresponding author. If given the opportunity, the corresponding author will submit the twice-revised manuscript along with a filled peer review response form (which is provided to him/her) and any other material requested to the editor-in-chief, who will judge whether the revisions undertaken can allow for the revised manuscript to be accepted for publication or rejected. Accepted manuscripts are processed by the editorial office. The latter communicates the manuscript acceptance form, the article proofs, the article proof correction form, and the article processing charge (APC) payment instructions to the corresponding author, who will need to return the filled and signed manuscript acceptance form as well as the article proof correction form to the editorial office within 72 h. Following this step, the article publication takes place after the confirmation of the payment of the APC.
6.1. Peer Review Process — The journal follows a standard single-blind (or single anonymized) peer review process by at least two reviewers. The editor-in-chief seeks the opinion of two independent reviewers who are invited to provide their expert opinion on the manuscript’s content within 10 days. One needs to factor in the time required for the editor-in-chief to identify and contact suitable reviewers, the time offered to allow them to reply to the invitation, and the time allowed for them to return their comments, along with the possibility that reviewers might drop out of the process at a later stage or might need to be replaced due to inactivity. In both latter cases, new reviewers have to be sought out for the assessment of the manuscript. Therefore, providing a reliable timeframe for this process is quite challenging. Authors of manuscripts submitted to the journal should expect to hear back from the editor-in-chief with the results of the first round of the peer review process within 21 to 40 days after the manuscript number assignment. The journal does not support a fast-track option for the peer review process.
6.2. Manuscript Status and Withdrawal — Corresponding authors can check their manuscript’s status with the editorial office by quoting the manuscript number. The withdrawal of a manuscript needs to be requested in writing by the corresponding author, and needs to be justified. If it transpires that the manuscript was submitted elsewhere while it was still under consideration by the journal, the editor-in-chief has the right to contact the publisher and the editor of other journal and request the manuscript’s rejection or the retraction of its published form (article).
7. OPEN-ACCESS FEES — The open-access fees are paid in the form of an article processing charge (APC) after the acceptance of the manuscript. The APC for a manuscript accepted for publication is provided in Table 2 and depends on the article type and the year in which the manuscript was first received. For manuscripts intended to be published in a special issue, a discount of 25% is applied.
| TABLE 2. Article processing charge (APC) for a manuscript accepted for publication in the journal Epitheorese Klinikes Farmakologias kai Farmakokinetikes, depending on the article type and the year of the manuscript’s first submission. |
| Article types | APC (in €) for manuscripts received in 2026 |
| Correspondence (response); Editorial; Obituary; Opinion (solicited) | n/a |
| All other article types | 300.00 |
8. PROCEEDINGS — The journal considers expressions of interest regarding the publishing of proceedings for conferences focusing on important or emerging topics in the wider fields of Clinical and Applied Pharmacology, Medicine, and Therapeutics. Depending on the agreement reached with the conference organisers, conference articles are published in either a full-text format (comprising a 200-word abstract, a 1,200-word main text, a maximum of 10 references, and one table or figure) or an abstract-only format (comprising a 500-word abstract). Templates and guidelines for the preparation and submission of proceedings article manuscripts are published only in the conference websites. The journal also offers the option of utilising the services of the journal’s consulting and proceedings editor in order to edit the conference proceedings, undertake extensive recordkeeping of the correspondence involved, and ensure the timely production of the supplementary issue.
9. SPECIAL ISSUES — The journal considers proposals regarding the organising of special issues that address important or emerging topics in the wider fields of Clinical and Applied Pharmacology, Medicine, and Therapeutics. Special issues are organised by no more than five members of the journal’s editorial board or guest editors, and can include any of the articles described in section 2. Such issues are published as supplementary issues, but if the final number of the accepted for publication manuscripts to be included in a special issue is lower than nine (excluding the editorial), the editor-in-chief retains the right to incorporate these articles into the next available regular issue of the journal as a thematic section. Manuscripts submitted for inclusion in a special issue undergo the standard peer-review process as any other manuscript would in the case of regular issue submissions. The open access fees for any accepted manuscript scheduled to be included in a special issue are subject to a discount of 25% (see section 7), while all accepted manuscripts scheduled to be included in a special issue are published only upon the completion of the special issue.